Mutational profile of PNMZL and PNMZL with overlapping PTFL features, compared with previously reported mutations in PTFL
| Gene . | Alteration frequency in PTFL (cases) . | Alteration frequency in PNMZL overlapping PTFL (cases) . | P . | Adjusted P . | Alteration frequency in PNMZL (cases) . | P . | Adjusted P . |
|---|---|---|---|---|---|---|---|
| MAP2K1 | 20/41 (48.8%) | 16/31 (51.6%) | 1.00 | 1.00 | 3/14 (21.4%) | .12 | .58 |
| TNFRSF14 | 21/41 (51.2%) | 10/24 (41.7%) | 0.61 | 1.00 | 3/12 (25%) | .19 | .67 |
| IRF8 | 13/37 (35.1%) | 8/22 (36.4%) | 1.00 | 1.00 | 4/13 (30.8%) | 1.00 | 1.00 |
| IRF8 (p.K66R) | 12/37 (32.4%) | 5/22 (22.7%) | .57 | 1.00 | 2/13 (15.4%) | .30 | .67 |
| IRF8 (p.Y23H) | 2/37 (5.4%) | 4/22 (18.2%) | .18 | .92 | 1/13 (7.7%) | 1.00 | 1.00 |
| EZH2 | 0/38 | 0/20 | 1.00 | 1.00 | 2/11 (18.2%) | .05 | .35 |
| FOXO1 | 1/38 (2.6%) | 1/20 (5%) | 1.00 | 1.00 | 0/11 | 1.00 | 1.00 |
| GNA13 | 4/38 (10.5%) | 1/20 (5%) | .65 | 1.00 | 0/11 | .56 | 1.00 |
| HIST1H1D | 0/38 | 0/20 | 1.00 | 1.00 | 1/11 (9.1%) | .22 | .67 |
| HIST1H1C | 1/38 (2.6%) | 1/20 (5%) | 1.00 | 1.00 | 0/11 | 1.00 | 1.00 |
| KMT2D | 6/38 (15.8%) | 0/24 | .07 | .55 | 0/12 | .31 | .79 |
| HIST1H1B | 1/38 (2.6%) | 0/20 | 1.00 | 1.00 | 0/11 | 1.00 | 1.00 |
| EP300 | 2/38 (5.3%) | 0/20 | .54 | 1.00 | 0/11 | 1.00 | 1.00 |
| CREBBP | 1/38 (2.6%) | 0/20 | 1.00 | 1.00 | 0/11 | 1.00 | 1.00 |
| TNFRSF14 biallelic inactivation | 15/39 (38.5%) | 3/23 (13%) | .04 | .55 | 0/12 | .01 | .16 |
| Gene . | Alteration frequency in PTFL (cases) . | Alteration frequency in PNMZL overlapping PTFL (cases) . | P . | Adjusted P . | Alteration frequency in PNMZL (cases) . | P . | Adjusted P . |
|---|---|---|---|---|---|---|---|
| MAP2K1 | 20/41 (48.8%) | 16/31 (51.6%) | 1.00 | 1.00 | 3/14 (21.4%) | .12 | .58 |
| TNFRSF14 | 21/41 (51.2%) | 10/24 (41.7%) | 0.61 | 1.00 | 3/12 (25%) | .19 | .67 |
| IRF8 | 13/37 (35.1%) | 8/22 (36.4%) | 1.00 | 1.00 | 4/13 (30.8%) | 1.00 | 1.00 |
| IRF8 (p.K66R) | 12/37 (32.4%) | 5/22 (22.7%) | .57 | 1.00 | 2/13 (15.4%) | .30 | .67 |
| IRF8 (p.Y23H) | 2/37 (5.4%) | 4/22 (18.2%) | .18 | .92 | 1/13 (7.7%) | 1.00 | 1.00 |
| EZH2 | 0/38 | 0/20 | 1.00 | 1.00 | 2/11 (18.2%) | .05 | .35 |
| FOXO1 | 1/38 (2.6%) | 1/20 (5%) | 1.00 | 1.00 | 0/11 | 1.00 | 1.00 |
| GNA13 | 4/38 (10.5%) | 1/20 (5%) | .65 | 1.00 | 0/11 | .56 | 1.00 |
| HIST1H1D | 0/38 | 0/20 | 1.00 | 1.00 | 1/11 (9.1%) | .22 | .67 |
| HIST1H1C | 1/38 (2.6%) | 1/20 (5%) | 1.00 | 1.00 | 0/11 | 1.00 | 1.00 |
| KMT2D | 6/38 (15.8%) | 0/24 | .07 | .55 | 0/12 | .31 | .79 |
| HIST1H1B | 1/38 (2.6%) | 0/20 | 1.00 | 1.00 | 0/11 | 1.00 | 1.00 |
| EP300 | 2/38 (5.3%) | 0/20 | .54 | 1.00 | 0/11 | 1.00 | 1.00 |
| CREBBP | 1/38 (2.6%) | 0/20 | 1.00 | 1.00 | 0/11 | 1.00 | 1.00 |
| TNFRSF14 biallelic inactivation | 15/39 (38.5%) | 3/23 (13%) | .04 | .55 | 0/12 | .01 | .16 |
Statistically significant P values are highlighted in bold.